Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that EGFR oncogenic variants status confers therapeutic sensitivity to Gefitinib in patients with Non-Small Cell Lung Cancer.
This statement is based on a regulatory approval from the Health Canada:
IRESSA (gefitinib) is indicated for the first line treatment of patients with locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) who have activating mutations of the EGFR-TK